Form 4: Alnylam Pharmaceuticals Director David E.I. Pyott Executes Stock Option and Sells Shares Under 10b5-1 Plan

Director David E.I. Pyott exercised stock options and sold shares of Alnylam Pharmaceuticals under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On March 24, 2025, David E.I. Pyott, a director of Alnylam Pharmaceuticals, exercised stock options to acquire 7,440 shares of common stock at a price of $88.95.
• Simultaneously, Pyott sold 7,440 shares of Alnylam common stock at $299 per share.
• These transactions were executed under a pre-arranged Rule 10b5-1(c) trading plan adopted on September 5, 2024.
• Following these transactions, Pyott directly owns 136 shares and indirectly owns 27,900 shares through a trust.
• The exercised options were set to expire on December 18, 2025, and were fully vested as of December 18, 2016.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing simply reports transactions under a pre-existing trading plan, which doesn't necessarily indicate a positive or negative outlook on the company's future.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, which is generally viewed as a transparent and compliant way for insiders to manage their stock holdings.

Risks

• While the 10b5-1 plan provides a framework, large sales by insiders can sometimes be perceived negatively by the market, potentially creating short-term price volatility.

Industry Context

Insider transactions are common in the pharmaceutical industry, where stock options are frequently part of executive compensation packages. Monitoring these transactions provides insights into management's perspective on the company's value and future prospects.

Comparison to Industry Standards

• Rule 10b5-1 trading plans are a common practice among corporate insiders across various industries, including pharmaceuticals, to manage their stock holdings while avoiding accusations of insider trading.
• Companies like Regeneron, Vertex, and Biogen also see frequent Form 4 filings related to stock option exercises and sales by their executives and directors.

Stakeholder Impact

• The transactions could have a minor impact on shareholders due to the potential for short-term price fluctuations following the sale of shares.

Key Dates

Keywords

Alnylam Pharmaceuticals, insider trading, Form 4, stock options, Rule 10b5-1, David E.I. Pyott, director, share sale